Annual Press Conference Business Year 2011

Size: px
Start display at page:

Download "Annual Press Conference 2012. Business Year 2011"

Transcription

1 Business Year 2011

2 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine

3 Value through Innovation Start of a new growth phase Again significant above-market growth Above-average investments in R&D Successful market placement of trajenta for type 2 diabetes Advances in future therapeutic areas - oncology and hepatitis C Actions over generations Our goal - long-term, organic growth 3

4 Our businesses 2011 Increase in net sales and operating income In EUR Net sales Operating income 12,586 million 13,171 million 1,896 million 2,272 million Increase in operating income Return on net sales 17.3% (previous year 15.1%) % growth on a euro basis Development of R&D expenses 2,453 million +63 million 2,516 million +6.2% growth (currency-adjusted) R&D expenses in Prescription Medicines corresponds to 23.5% of its net sales 4

5 Boehringer Ingelheim on growth course Group Core products and new launches Growth in net sales Operating income increased Start of a growth phase trajenta pradaxa spiriva Strategic potential Growth in new markets Biopharmaceuticals - new biological entities and biosimilars Animal Health - focus on animal vaccines Development portfolio Significant progress with clinical development portfolio Oncology and hepatitis C Idiopathic lung fibrosis, asthma 5

6 Global market performance Growth exceeds the pharmaceutical market Global market share Growth in constant EUR (%) NOVO NORDISK 1.32% MYLAN 1.08% OTSUKA 1.22% * BOEHRINGER INGELHEIM 1.93% BRISTOL-MYERS SQB. 1.94% NOVARTIS 6.02% LILLY 2.82% MERCK & CO 4.76% ABBOTT 3.02% AMGEN 1.95% Roche 4.06% DAIICHI SANKYO + RANBAXY 1.27% BAYER SCHERING 1.90% TAKEDA 2.13% ASTRAZENECA 4.40% SANOFI 4.52% GLAXOSMITHKLINE 4.01% JOHNSON & JOHNSON 3.25% PFIZER 6.68% TEVA + RATIOPHARM 2.84% Boehringer Ingelheim Global market share: 1.93% Note: This data represents 96% of IMS Global MIDAS sales data. 6

7 Businesses and Financial Figures 2011 Hubertus von Baumbach Corporate Board Division Finance and Animal Health

8 Challenges in 2011 successfully overcome - Significant improvement in income in EUR million Change Net sales 12,586 13, % Growth +6.2% (currency-adjusted) Operating income 1,896 2, % Equity ratio 39.9% 40.0% Financial funds 6,113 7, % Solid financing Increase in liquidity 8

9 Prescription Medicines Gratifying growth Net sales in EUR million 12,586 13,171 Growth of +5.3% (currency-adjusted) 77% of Group net sales In particular due to pradaxa and spiriva Prescription Medicines 9,702 10,096 Decline in sales of sifrol after patent expiry Launch of trajenta in

10 Prescription Medicines Equal growth of newly launched and established products Net sales in EUR million, growth (currency-adjusted) 3,153 1, % +6.6% % >100 % 29.5% spiriva micardis -family combivent pradaxa sifrol /mirapex 10

11 Consumer Health Care Gratifying growth Net sales in EUR million Consumer Health Care 12,586 1,318 13,171 1,396 Growth +7.1% (currency-adjusted) 11% of Group net sales Emerging markets +16.7%

12 Consumer Health Care Strong growth of international core brands Net sales in EUR million, growth (currency-adjusted) Market position* #1 #1 #2 #3 # % +10.1% % % % buscopan dulcolax mucosolvan pharmaton bisolvon * Source: MAT 09/2011 IMS OTC Rv+ Q

13 Animal Health Successful vaccines drive growth Net sales in EUR million Animal Health 12, , Growth +7.8% (currency-adjusted) 7% of Group net sales Boehringer Ingelheim is growing faster than the market, retains 6th place Swine vaccines main growth driver

14 Animal Health Successful research network New animal vaccines give better prevention Our global research and development sites European Centre for Animal Vaccines, Hanover (Germany) St. Joseph (USA) Guadalajara (Mexico) Asian Veterinary Research and Development Centre, Shanghai (China) 14

15 Animal Health Strong growth of top 5 products Net sales in EUR million, growth (currency-adjusted) % +3.0% +32.5% +10.7% +2.7% ingelvac metacam ingelvac prrs vetmedin ingelvac mhyo circoflex 15

16 Industrial Customer Business Biopharmaceuticals main driver Net sales in EUR million Industrial Customer Business 12, , Growth +9.2% (currency-adjusted) 5% of Group net sales Biopharmaceuticals make up 74% of the Industrial Customer Business

17 Established Markets Still highly important for our business Net sales in EUR million Global 13,171 Top 3 countries 58% Top 10 countries 76% USA Japan 1,831 4,820 USA, Japan, Germany Prescription Medicines Consumer Health Care Animal Health R&D and Operations Biopharmaceuticals in USA, Germany Germany 950 Number of employees in Top 3 countries USA 10,016 Japan 2,832 Germany 12,501 17

18 Boehringer Ingelheim committed to Germany 46% of Group investments - EUR 210 million thereof EUR 156 million in Ingelheim for the expansion of pradaxa production (116 new jobs in Operations) 50% of total expenditure for R&D employees in Germany, +333 employees 18

19 Emerging markets Dynamic growth and future potential Growth in net sales in % (currency-adjusted) Russia China South America MENA +35.1% +30.2% +25.5% +19.1% Russia High net sales growth due to successful regionalisation, workforce continues to grow significantly South America Considerable net sales growth in Argentina and Colombia MENA (Middle East/North Africa) Establishment of organisation and expansion of product portfolio especially in North Africa 19

20 China Strong growth and expansion of operating activities Net sales growth > +30% essentially due to mucosolvan, micardis and spiriva Large rise in workforce to 2,701 (+31.4%) Investment in production facility at Zhangjiang High-Tech Park, Shanghai R&D - participation in global development programmes for diabetes, oncology and respiratory diseases Animal Health - Asian Veterinary Research and Development Centre, development of vaccines for Asia 20

21 Profitable growth Increase in operating income and profitability in EUR million Change Net sales 12,586 13, % Operating income 1,896 2, % Financial income % Extraordinary result Income before taxes 1,114 2, % Currency effect on net sales 1.6% Increase in R&D expenditure to EUR 2,516 million (+2.6%) extraordinary expense mainly affected by change in pension accounting (BilMoG/one-time effect) Taxes Net income 888 1, % 21

22 Cash flow from operating activities covers investing activities Cash flow in EUR million , ,056 Cash flow from operating activities EUR 514 million higher than in 2010 Cash flow from financing activities also includes withdrawals for shareholders tax payments Strong rise in financial funds on an ongoing basis 1,602 Operating activities Investing activities Financing activities Changes in financial funds* * Without changes in financial funds due to exchange rate movements 22

23 Sustainable business development over past 10 years Employees 31,843 34,221 35,529 37,406 38,428 39,800 41,300 41,534 42,224 44,094 in EUR million 2,109 2,215 2,453 2,516 1,900 1,574 R&D 1,304 1,176 1,232 1,360 13,171 12,721 12,586 expenditure 11,595 10,952 10,574 Net sales 7,580 7,382 8,157 9,535 Operating income 1, ,372 1,923 2,140 2,100 1,980 2,239 1,896 2,

24 Outlook 2012 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine

25 pradaxa for the prevention of stroke in patients with atrial fibrillation High medical demand Improved prevention and treatment of acute and chronic thromboembolic diseases Therapeutic breakthrough - reduced risk of stroke 25

26 trajenta for the treatment of type 2 diabetes High medical demand and excellent growth potential No dose adjustment and monitoring necessary in older patients and patients with a risk of impaired renal function First milestone in successful partnership with Eli Lilly Further potential in the diabetes development pipeline 26

27 Our Research and Development Substances in advanced clinical development Anticoagulation Dabigatran etexilate, (pradaxa ) - Treatment and secondary prevention of VTE Phase III Type 2 diabetes Empagliflozin, SGLT-2 inhibitor Oncology Afatinib, irreversible tyrosine kinase inhibitor Nintedanib, triple angiokinase inhibitor Volasertib, polo-like kinase inhibitor Hepatitis C BI201335, protease inhibitor BI207127, polymerase inhibitor Respiratory diseases Nintedanib, antifibrotic kinase inhibitor, IPF Tiotropium (LAMA) + Olodaterol (LABA), COPD Tiotropium (LAMA) monotherapy, asthma Phase III Phase III Phase III Phase II Phase III Phase II Phase III Phase III Phase III 27

28 Cooperation with basic research Investment in treatments of the future Academic partnerships Stanford University (USA) Karolinska Institutet (Sweden) Boehringer Ingelheim University Ulm Biocenter (Germany) Johannes Gutenberg-Universität Mainz (Germany) Technische Universität Dresden (Germany) Boehringer Ingelheim Venture Fund Institute of Molecular Pathology, Vienna (Austria) Institute of Molecular Biology, Mainz (Germany) 28

29 Biopharmaceuticals Biosimilars and NBE development Entire biopharmaceutical process chain covered Development service for all clinical phases - from protein scaffolds to antibodies Production of new biological entities (NBE) and biosimilars Technology platforms for contract manufacturing 29

30 Our employees Respect, trust, empathy and passion Together we create the future of Boehringer Ingelheim Special corporate culture Establishing entrepreneurial processes Safeguarding innovative capabilities Talent management Leadership development Diversity and inclusion 30

31 Outlook 2012 Guide our own R&D to success Launch of drugs in the following areas Diabetes Oncology Hepatitis C Idiopathic pulmonary fibrosis Asthma Entering new therapeutic areas pradaxa - new market launches and enhanced positioning trajenta - new market launches and enhanced positioning Establishment of oncology and hepatitis C Implement strategy Organic growth strategy Expansion of biopharmaceuticals, process development, production of biological entities Expansion of Animal Health, focus on vaccines Safeguarding sustainable independence Continuation of growth phase Forecast for sound, high single-digit growth Maintain high level of investment in R&D 31

32 Business Year 2011

Boehringer Ingelheim Annual Press Conference 2015. Wednesday, 22 April 2015 Boehringer Ingelheim Center, Ingelheim, Germany

Boehringer Ingelheim Annual Press Conference 2015. Wednesday, 22 April 2015 Boehringer Ingelheim Center, Ingelheim, Germany Boehringer Ingelheim Annual Press Conference 2015 Wednesday, 22 April 2015 Boehringer Ingelheim Center, Ingelheim, Germany The remarks of Andreas Barner Hubertus von Baumbach Members of the Board of Managing

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

NEWS FROM THERAPEUTIC AREAS

NEWS FROM THERAPEUTIC AREAS HIGHLIGHTS IN MEDICINE IN 2014 NEWS FROM THERAPEUTIC AREAS Research, development and medicine at Boehringer Ingelheim can look back on yet another very successful year. Research, development and medicine

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries

More information

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors

More information

ABCD. Welcome to BICI. Petersburg, Virginia

ABCD. Welcome to BICI. Petersburg, Virginia Welcome to BICI Petersburg, Virginia Our Company Our Worldwide Company in Brief: - Focus on Human Pharmaceuticals and Animal Health - Founded 1885 in Ingelheim, Germany - Products marketed in some 150

More information

Brochure More information from http://www.researchandmarkets.com/reports/3292678/

Brochure More information from http://www.researchandmarkets.com/reports/3292678/ Brochure More information from http://www.researchandmarkets.com/reports/3292678/ Asia Pacific (India, China, Australia, South Korea & Others) Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long

More information

Breast Cancer Drug Discoveries: What the Future Holds

Breast Cancer Drug Discoveries: What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to

More information

Pharma working capital performance highly variable

Pharma working capital performance highly variable April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the

More information

The Hong Kong Association of The Pharmaceutical Industry

The Hong Kong Association of The Pharmaceutical Industry The Hong Kong Association of The Pharmaceutical Industry UNIT A, 20/F., TIMES MEDIA CENTRE, FAX: (852) 2865 6283 WEBSITE: www. hkapi.hk Position Paper on the Pharmacy and Poisons (Amendment) Bill 2014

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics

More information

Summary Report 2009. Value through Innovation. nopq

Summary Report 2009. Value through Innovation. nopq Summary Report 2009 Value through Innovation nopq Financial Highlights Boehringer Ingelheim group of companies Amounts in millions of EUR, unless otherwise indicated 2009 2008 change Net sales 12,721 11,595

More information

Global Peptide Therapeutics Market 2014-2018

Global Peptide Therapeutics Market 2014-2018 Brochure More information from http://www.researchandmarkets.com/reports/3022209/ Global Peptide Therapeutics Market 2014-2018 Description: About Peptide Therapeutics Peptides are amino acids sequences

More information

Breakfast symposium: From hospital to home - the focus on the patient

Breakfast symposium: From hospital to home - the focus on the patient Breakfast symposium: From hospital to home - the focus on the patient Nadya Hamedi DARZI Fellow UCLPartners and Barts Health NHS Trust in collaboration with North Central London Local Pharmaceutical Committee

More information

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Commercial Insight Osteoarthritis and Rheumatoid Arthritis A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

- Understand Datamonitor's independent appraisal of marketed oral anticoagulant brands and key pipeline agents indicated for treating SPAF.

- Understand Datamonitor's independent appraisal of marketed oral anticoagulant brands and key pipeline agents indicated for treating SPAF. Brochure More information from http://www.researchandmarkets.com/reports/2236696/ Product Profiles: Stroke Prevention in Atrial Fibrillation - Uptake slower than expected for the first warfarin alternatives,

More information

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials

More information

PHARMACEUTICAL INDUSTRY PROFILE

PHARMACEUTICAL INDUSTRY PROFILE PHARMACEUTICAL INDUSTRY PROFILE I. INDUSTRY BACKGROUND A. Industry Definition The U.S. pharmaceutical industry is defined by the Census Bureau as companies engaged in researching, developing, manufacturing,

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions

More information

Most countries will experience an increase in pharmaceutical spending per capita by 2018

Most countries will experience an increase in pharmaceutical spending per capita by 2018 6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan

More information

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality 6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors

More information

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S. Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint

More information

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?

More information

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness

More information

Global Pharmaceuticals Marketing Channel Reference EDITION

Global Pharmaceuticals Marketing Channel Reference EDITION Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry

More information

Slide 1. Virksomhedsdagen 2013 Den Danske Finansanalytikerforening. Jesper Brandgaard, CFO. June 2013

Slide 1. Virksomhedsdagen 2013 Den Danske Finansanalytikerforening. Jesper Brandgaard, CFO. June 2013 Slide 1 Virksomhedsdagen 2013 Den Danske Finansanalytikerforening Jesper Brandgaard, CFO June 2013 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities

More information

EvaluatePharma World Preview 2015, Outlook to 2020

EvaluatePharma World Preview 2015, Outlook to 2020 EvaluatePharma World Preview 2015, Outlook to 2020 8th Edition June 2015 Welcome to the EvaluatePharma World Preview 2015, Outlook to 2020 The eighth edition of EvaluatePharma s World Preview brings together

More information

ehealthinsight Series: Online Patient Recruitment Strategies

ehealthinsight Series: Online Patient Recruitment Strategies A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient

More information

Adherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015

Adherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015 Adherence to NOACs Patricia van den Bemt EAHP Hamburg 2015 Disclosure Unrestricted research grants from Glaxo-SmithKline Boehringer Ingelheim Daiichi Sankyo Bayer Pfizer For research on medication safety

More information

Poxel Raises 16 million in a Series A Financing to Accelerate Pipeline Development

Poxel Raises 16 million in a Series A Financing to Accelerate Pipeline Development Poxel Raises 16 million in a Series A Financing to Accelerate Pipeline Development Lyon, France, July 8, 2010 -, a diabetes drug development specialist, announces today that it has raised 16 million (USD

More information

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78

More information

Commerzbank Sector Conference. Frankfurt August 30, 2011

Commerzbank Sector Conference. Frankfurt August 30, 2011 Commerzbank Sector Conference Frankfurt August 30, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Pharmaceutical industry

Pharmaceutical industry 8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

Medivir s financial reports are available from its Website, www.medivir.se from these dates, under the Financial Information heading.

Medivir s financial reports are available from its Website, www.medivir.se from these dates, under the Financial Information heading. PRESS RELEASE, 23 October INTERIM REPORT, 1 January - 30 September In July, Medivir entered a licensing agreement with Boehringer Ingelheim (BI) on MIV-310. CCS group divested to the Segulah II L.P. investment

More information

Pharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success

Pharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success Pharmaceuticals Production Services Boehringer Ingelheim Our expertise in world-class contract manufacturing for your success Successful partnership Dr Wolfram Carius Head of Corporate Division Pharmaceuticals

More information

Healthcare, Regulatory and Reimbursement Landscape - Australia

Healthcare, Regulatory and Reimbursement Landscape - Australia Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape

More information

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:

More information

Quo vadis Pharmaceutical Industry? New strategies to overcome the innovation gap

Quo vadis Pharmaceutical Industry? New strategies to overcome the innovation gap Quo vadis Pharmaceutical Industry? New strategies to overcome the innovation gap Jochen Maas Stuttgart, May 2014 Quo vadis Pharmaceutical Industry? R&D in the pharmaceutical industry - still a valid model?

More information

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo to Acquire Ambit Biosciences For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please

More information

Louise Mehrotra. Vice President Investor Relations

Louise Mehrotra. Vice President Investor Relations Louise Mehrotra Vice President Investor Relations Safe Harbor Statement This presentation may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These

More information

Annual Report 2007. nopq

Annual Report 2007. nopq Annual Report 2007 Value Value through through Innovation nopq Financial Highlights Boehringer Ingelheim group of companies Amounts in millions of EUR, unless otherwise indicated 2007 2006 change Net sales

More information

Commercial Perspectives: Multiple Sclerosis

Commercial Perspectives: Multiple Sclerosis A Datamonitor Report Commercial Perspectives: Multiple Sclerosis How to Find Opportunities in an Unremitting Market Published: Jun-04 Product Code: Providing you with: In-depth profiles of current market-leading

More information

Stakeholder Insight: Insulin Use in Type 2 Diabetes

Stakeholder Insight: Insulin Use in Type 2 Diabetes A Datamonitor Report Stakeholder Insight: Insulin Use in Type 2 Diabetes From Last Resort to Early Intervention Published: May-04 Product Code: DMHC1989 Providing you with: Analysis of Datamonitor s Diabetes

More information

Medical Writing Takes Off in India

Medical Writing Takes Off in India Visit http://store.centerwatch.com to learn more about State of the Clinical Trials Industry 2008 Special Article Reprint For the latest news and views on the clinical trials industry visit ClinicalTrialsToday.com

More information

UBS Global Life Sciences Conference 2011. New York September 19, 2011

UBS Global Life Sciences Conference 2011. New York September 19, 2011 UBS Global Life Sciences Conference 2011 New York September 19, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the

More information

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Paulina Ramirez: Birmingham Business School IRIMA Workshop on the Internationalisation

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical

More information

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage

More information

Rx-360 An International Pharmaceutical Supply Chain Consortium

Rx-360 An International Pharmaceutical Supply Chain Consortium Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)

More information

Enhancing Value With Financial & Operational Excellence

Enhancing Value With Financial & Operational Excellence Enhancing Value With Financial & Operational Excellence Robert Hombach CFO & COO Enhancing Value With Financial & Operational Excellence Growing Sales & Earnings Generating value in attractive markets

More information

KEEPING CLINICAL TRIALS IN AUSTRALIA

KEEPING CLINICAL TRIALS IN AUSTRALIA OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought

More information

Global outlook: Healthcare

Global outlook: Healthcare Global outlook: Healthcare March 2014 healthcare 1 Today s presenters Ana Nicholls Managing Editor, Industry Briefing Economist Intelligence Unit Lauren Brayshaw Marketing executive Economist Intelligence

More information

Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies

Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies The Pharma Industry s Reputation in the Eyes of the General Public A Reputation Study with Consumers in 15 Countries RepTrak is a

More information

SAVAYSA (edoxaban) U.S. Opportunity

SAVAYSA (edoxaban) U.S. Opportunity SAVAYSA (edoxaban) U.S. Opportunity February 17, 2015 Ken Keller President, U.S. Commercial DSI, Inc. Key Discussion Points Daiichi Sankyo, Inc. (DSI) in the U.S. SAVAYSA (edoxaban) U.S. Indication NOAC

More information

ZENTIVA A SANOFI COMPANY. Corporate Presentation

ZENTIVA A SANOFI COMPANY. Corporate Presentation ZENTIVA A SANOFI COMPANY Corporate Presentation SANOFI A global healthcare leader, focused on patients needs SANOFI A global integrated healthcare leader, focused on patients needs CORPORATE PRESENTATION

More information

(1) MAJOR TRANSACTION ACQUISITION OF FURTHER EQUITY INTERESTS IN SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD.; AND (2) CHANGE IN USE OF PROCEEDS

(1) MAJOR TRANSACTION ACQUISITION OF FURTHER EQUITY INTERESTS IN SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD.; AND (2) CHANGE IN USE OF PROCEEDS Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness

More information

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012 The power of creativity www.originbranding.com Pharmaceutical Branding 2012 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered

More information

9. WestLB Deutschland Conference. Frankfurt November 16, 2011

9. WestLB Deutschland Conference. Frankfurt November 16, 2011 9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

ABCD. Welcome to BICI. Petersburg, Virginia

ABCD. Welcome to BICI. Petersburg, Virginia Welcome to BICI Petersburg, Virginia Our Company Our Worldwide Company in Brief: - Focus on Human Pharmaceuticals and Animal Health - Founded 1885 in Ingelheim, Germany - Products marketed in some 150

More information

Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG

Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG Company Presentation July 2013 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and its

More information

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment

More information

Deutsches Eigenkapitalforum. Frankfurt November 22, 2011

Deutsches Eigenkapitalforum. Frankfurt November 22, 2011 Deutsches Eigenkapitalforum Frankfurt November 22, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

REFERENCE CODE GDHC87PIDR PUBLICATION DATE FEBRUARY 2015 ATRIAL FIBRILLATION GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC87PIDR PUBLICATION DATE FEBRUARY 2015 ATRIAL FIBRILLATION GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC87PIDR PUBLICATION DATE FEBRUARY 2015 ATRIAL FIBRILLATION GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Table below provides the key metrics for atrial fibrillation

More information

Indian Vaccines Report

Indian Vaccines Report Brochure More information from http://www.researchandmarkets.com/reports/595558/ Indian Vaccines Report Description: "Vaccine manufacturers from all over the world have been involved in a stalemate with

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

INTERIM REPORT, 1 January - 30 June 2003

INTERIM REPORT, 1 January - 30 June 2003 PRESS RELEASE, 9 July INTERIM REPORT, 1 January - 30 June In May, Medivir reached a licensing agreement on MIV-210 with GlaxoSmithKline; EUR 6 m was received upon signing and up to EUR 86 m on the achievement

More information

Cardiology Update 2014

Cardiology Update 2014 Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The

More information

Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update

Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update August 10, 2015 Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update DUBLIN, IRELAND -- (Marketwired) -- 08/10/15 -- Theravance Biopharma, Inc. (NASDAQ:

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

Licence for use in the UK is expected before the end of 2011

Licence for use in the UK is expected before the end of 2011 News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval

More information

Louise Mehrotra. Vice President, Investor Relations

Louise Mehrotra. Vice President, Investor Relations Louise Mehrotra Vice President, Investor Relations Safe Harbor Statement This presentation may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These

More information

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim Prof. Florian Gantner Vice President Respiratory Diseases Research Boehringer Ingelheim Research and Development in Practice: COPD Chronic Obstructive Pulmonary Disease (COPD) Facts Main cause of COPD

More information

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011 Kempen & Co 4 th Healthcare/Life Sciences Conference Brussels March 29, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included

More information

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global Content Management in the Pharmaceutical Industry An Overview Blockbuster!!! Avatar USD 2 Billion revenues Lipitor USD 12.5 Billion in 2008 Dr Arun Gangatkar http://in.linkedin.com/in/drarungangatkar drarunj@gmail.com

More information

using the fully human ADLib system

using the fully human ADLib system Company Research and Analysis Report FISCO Ltd. http://www.fisco.co.jp 伪 伪 Focusing on improving technology to obtain antibodies using the fully human ADLib system (4583) (subsequently, the company ) is

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical

More information

Global Market Study on Sleep Aids: Sleep Apnea to Witness Highest Growth by 2020

Global Market Study on Sleep Aids: Sleep Apnea to Witness Highest Growth by 2020 Brochure More information from http://www.researchandmarkets.com/reports/3422615/ Global Market Study on Sleep Aids: Sleep Apnea to Witness Highest Growth by 2020 Description: Sleep aids are pills and

More information

About the RECORD Clinical Trial Program

About the RECORD Clinical Trial Program About the RECORD Clinical Trial Program Fast facts RECORD was a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism

More information

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is

More information

EVT Execute & EVT Innovate Leading drug discovery

EVT Execute & EVT Innovate Leading drug discovery EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

The Board reviews risks to the Company s business plan at its scheduled meetings.

The Board reviews risks to the Company s business plan at its scheduled meetings. Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board

More information

The Rise of China: Implications for Pharma and Pharma Librarians

The Rise of China: Implications for Pharma and Pharma Librarians The Rise of China: Implications for Pharma and Pharma Librarians Pharmaceutical & Health Technology Division Special Libraries Association March 20, 2012 Essential Insight for the Healthcare Industry Agenda

More information

Building innovative drug discovery alliances. Profitable. Growth Go

Building innovative drug discovery alliances. Profitable. Growth Go Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains

More information

In the largest and perhaps the most ambitious collaborative

In the largest and perhaps the most ambitious collaborative FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

More information

Cegedim Half-year results 2009 September 2009

Cegedim Half-year results 2009 September 2009 Cegedim Half-year results 2009 September 2009 1 Cegedim : Healthcare - its primary market Cegedim Founded in 1969 by Jean-Claude Labrune Jean-Claude Labrune family hold 67 % of Cegedim through FCB 849

More information

Industry Insight - Indian Biopharma

Industry Insight - Indian Biopharma Brochure More information from http://www.researchandmarkets.com/reports/2043221/ Industry Insight - Indian Biopharma Description: Biopharmaceuticals are complex macromolecules (Large molecules) created

More information

WHITE PAPER PHARMERGING MARKETS. Pharmerging markets. Picking a pathway to success

WHITE PAPER PHARMERGING MARKETS. Pharmerging markets. Picking a pathway to success WHITE PAPER PHARMERGING MARKETS Pharmerging markets Picking a pathway to success PHARMERGING MARKETS 1 With slow growth for pharmaceutical sales in developed markets, multinational companies (MNCs) have

More information

Novel Anticoagulants

Novel Anticoagulants Novel Anticoagulants Mark T. Reding, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation Director, Center for Bleeding and Clotting Disorders University of Minnesota

More information

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Appendix C Factors to consider when choosing between anticoagulant options and FAQs Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened

More information

The Global Alliance against Chronic Respiratory Diseases

The Global Alliance against Chronic Respiratory Diseases The Global Alliance against Chronic Respiratory Diseases Pulmonary hypertension Dr Marc Humbert What is the burden of pulmonary hypertension? The true burden of pulmonary hypertension is currently unknown

More information

SHORT CLINICAL GUIDELINE SCOPE

SHORT CLINICAL GUIDELINE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2

More information

New York Bio Conference 2016. Mark J. Alles Chief Executive Officer

New York Bio Conference 2016. Mark J. Alles Chief Executive Officer New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root

More information